Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThalDoDex induction therapy for multiple myeloma (phase II)
2006-005831-44Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide, pegylated liposomal doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by European Institute of Oncology. Primary endpoint: Overall response rate. Started Jun 2007; status: completed.
02
Drugs
thalidomidepegylated liposomal doxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-005831-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005831-44.